XLON
PXS
Market cap24mUSD
Jul 16, Last price
0.78GBP
1D
0.00%
1Q
40.91%
Jan 2017
-8.82%
IPO
-87.55%
Name
Provexis PLC
Chart & Performance
Profile
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
Income | |||||||||
Revenues | 802 105.68% | 390 -8.51% | |||||||
Cost of revenue | 1,285 | 811 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (483) | (421) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (14) | (33) | |||||||
Tax Rate | |||||||||
NOPAT | (469) | (388) | |||||||
Net income | (586) 52.18% | (385) 71.79% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 35 | ||||||||
BB yield | -0.20% | ||||||||
Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (189) | (379) | |||||||
Cash flow | |||||||||
Cash from operating activities | (191) | (520) | |||||||
CAPEX | |||||||||
Cash from investing activities | 2 | 887 | |||||||
Cash from financing activities | 35 | ||||||||
FCF | (68) | (523) | |||||||
Balance | |||||||||
Cash | 189 | 379 | |||||||
Long term investments | |||||||||
Excess cash | 149 | 360 | |||||||
Stockholders' equity | (18,513) | (11,446) | |||||||
Invested Capital | 18,703 | 12,093 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 2,217,822 | 2,216,805 | |||||||
Price | 0.01 -20.89% | 0.01 -7.06% | |||||||
Market cap | 13,861 -20.85% | 17,513 -6.81% | |||||||
EV | 13,138 | 16,602 | |||||||
EBITDA | (483) | (421) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |